Search

Author/Creator Hoffman, Robert W

1. 185 Baricitinib-associated changes in type I interferon gene signature during a 24-week phase 2 clinical SLE trial. (April 2019)

Authors:
Dörner, Thomas; Tanaka, Yoshiya; Petri, Michelle; Smolen, Josef S; Dow, Ernst R; Higgs, Richard E; Benschop, Robert J; Abel, Adam; Silk, Maria E; Bono, Stephanie de; Hoffman, Robert W
Journal:
Lupus science & medicine
Issue:
Volume 6(2019)supplement 1
Page Start:
A141
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 199 Baricitinib in patients with systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study. (April 2019)

Authors:
Silk, Maria E; Wallace, Daniel J; Furie, Richard A; Tanaka, Yoshiya; Kalunian, Kenneth C; Mosca, Marta; Petri, Michelle; Dörner, Thomas; Cardiel, Mario H; Bruce, Ian N; Gomez, Elisa; DeLozier, Amy M; Janes, Jonathan M; Linnik, Matthew D; Bono, Stephanie de; Hoffman, Robert W
Journal:
Lupus science & medicine
Issue:
Volume 6(2019)supplement 1
Page Start:
A149
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 611 Efficacy and safety of nipocalimab in adult patients with active systemic lupus erythematosus: design of a phase 2 study. (14th December 2022)

Authors:
Liu-Walsh, Fang; Hartingsveldt, Bart van; Zuraw, Qing; Hoffman, Robert W; Rooney, Terence; Gao, Sheng; Gordon, Robert; Leu, Jocelyn H; Calderon, Cesar; Zazzetti, Federico; Stevens, Anne M; Vratsanos, George
Journal:
Lupus science & medicine
Issue:
Volume 9(2022)Supplement 3
Page Start:
A35
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Issue 10143 (21st July 2018)

Authors:
Wallace, Daniel J; Furie, Richard A; Tanaka, Yoshiya; Kalunian, Kenneth C; Mosca, Marta; Petri, Michelle A; Dörner, Thomas; Cardiel, Mario H; Bruce, Ian N; Gomez, Elisa; Carmack, Tara; DeLozier, Amy M; Janes, Jonathan M; Linnik, Matthew D; de Bono, Stephanie; Silk, Maria E; Hoffman, Robert W
Journal:
Lancet
Issue:
Volume 392:Issue 10143(2018)
Page Start:
222
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Issue 1 (9th October 2020)

Authors:
Dörner, Thomas; Tanaka, Yoshiya; Petri, Michelle A; Smolen, Josef S; Wallace, Daniel J; Dow, Ernst R; Higgs, Richard E; Rocha, Guilherme; Crowe, Brenda; Benschop, Robert J; Byers, Nicole L; Silk, Maria E; de Bono, Stephanie; Fantini, Damiano; Hoffman, Robert W
Journal:
Lupus science & medicine
Issue:
Volume 7:Issue 1(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Issue 1 (9th October 2020)

Authors:
Dörner, Thomas; Tanaka, Yoshiya; Petri, Michelle A; Smolen, Josef S; Wallace, Daniel J; Dow, Ernst R; Higgs, Richard E; Rocha, Guilherme; Crowe, Brenda; Benschop, Robert J; Byers, Nicole L; Silk, Maria E; de Bono, Stephanie; Fantini, Damiano; Hoffman, Robert W
Journal:
Lupus science & medicine
Issue:
Volume 7:Issue 1(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Issue 1 (9th October 2020)

Authors:
Dörner, Thomas; Tanaka, Yoshiya; Petri, Michelle A; Smolen, Josef S; Wallace, Daniel J; Dow, Ernst R; Higgs, Richard E; Rocha, Guilherme; Crowe, Brenda; Benschop, Robert J; Byers, Nicole L; Silk, Maria E; de Bono, Stephanie; Fantini, Damiano; Hoffman, Robert W
Journal:
Lupus science & medicine
Issue:
Volume 7:Issue 1(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Issue 1 (9th October 2020)

Authors:
Dörner, Thomas; Tanaka, Yoshiya; Petri, Michelle A; Smolen, Josef S; Wallace, Daniel J; Dow, Ernst R; Higgs, Richard E; Rocha, Guilherme; Crowe, Brenda; Benschop, Robert J; Byers, Nicole L; Silk, Maria E; de Bono, Stephanie; Fantini, Damiano; Hoffman, Robert W
Journal:
Lupus science & medicine
Issue:
Volume 7:Issue 1(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Issue 1 (9th October 2020)

Authors:
Dörner, Thomas; Tanaka, Yoshiya; Petri, Michelle A; Smolen, Josef S; Wallace, Daniel J; Dow, Ernst R; Higgs, Richard E; Rocha, Guilherme; Crowe, Brenda; Benschop, Robert J; Byers, Nicole L; Silk, Maria E; de Bono, Stephanie; Fantini, Damiano; Hoffman, Robert W
Journal:
Lupus science & medicine
Issue:
Volume 7:Issue 1(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗